PNC Financial Services Group Inc. Raises Holdings in Insulet Co. (NASDAQ:PODD)

PNC Financial Services Group Inc. increased its position in Insulet Co. (NASDAQ:PODD) by 7.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 12,969 shares of the medical instruments supplier’s stock after buying an additional 886 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Insulet were worth $3,019,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Blue Trust Inc. raised its position in shares of Insulet by 84.1% in the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 58 shares during the period. International Assets Investment Management LLC purchased a new position in shares of Insulet in the 2nd quarter worth $32,000. Venturi Wealth Management LLC raised its position in shares of Insulet by 633.3% in the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 133 shares during the period. UMB Bank n.a. raised its position in shares of Insulet by 81.0% in the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock worth $37,000 after buying an additional 81 shares during the period. Finally, CVA Family Office LLC raised its position in shares of Insulet by 138.1% in the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock worth $50,000 after buying an additional 145 shares during the period.

Analysts Set New Price Targets

Several research analysts have commented on the company. Canaccord Genuity Group raised their price objective on Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. UBS Group raised their price objective on Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research report on Friday, August 9th. Raymond James raised their price objective on Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research report on Monday, October 14th. Piper Sandler raised their price objective on Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a research report on Tuesday, September 17th. Finally, BTIG Research raised their price objective on Insulet from $260.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Three analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, Insulet presently has a consensus rating of “Moderate Buy” and a consensus target price of $253.27.

Insulet Stock Up 0.4 %

NASDAQ:PODD opened at $262.93 on Monday. The company has a market capitalization of $18.44 billion, a price-to-earnings ratio of 45.02, a price-to-earnings-growth ratio of 4.01 and a beta of 1.22. Insulet Co. has a one year low of $160.19 and a one year high of $279.40. The stock has a 50-day simple moving average of $241.32 and a 200 day simple moving average of $211.02. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.